Social Media Ideas for Lundbeck

Portugal ganha peso na estratégia ibérica da Lundbeck e afirma-se como hub de inovação clínica

A farmacêutica dinamarquesa Lundbeck está a reforçar o papel de Portugal na sua estratégia ibérica, num momento em que o grupo aposta na expansão da inovação em neurociência. Integ...

AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline

<![CDATA[Eli Lilly to Acquire AtaiBeckley for $2.8 Billion ]]>

<![CDATA[M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Part...

<![CDATA[Pharmaceutical Executive Daily: Novo Nordisk Files Lawsuit Against Eli Lilly]]>

Pharmacosmos Therapeutics

Pharmacosmos Therapeutics Anonymous (not verified) Wed, 07/29/2026 - 18:25 field_thread_url https://cafepharma.com/boards/threads/pharmacosmos-therapeutics...

<![CDATA[M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration wit...

Lilly Expands Its Mind to Psychedelics With $2.8B AtaiBeckley Acquisition

Eli Lilly’s AtaiBeckley acquisition marks a dozen M&A deals for the pharma company so far this year. AtaiBeckley’s lead program is an intranasally administered psychedelic drug...

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley a Good Trip for Psychedelic Drugs, Analysts and Investors Agree

Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion—of which Lilly will pay $2.8 billion upfront. The deal, set to close in the third quarter, expands Lilly’s neuroscien...

Genmab

Genmab Anonymous (not verified) Mon, 07/13/2026 - 12:14 field_thread_url https://cafepharma.com/boards/threads/genmab.680642/ board name...

Herz-Medikament: Novo Nordisk mit Entwicklungsfehlschlag – Aktienkurs sackt ab

Der dänische Pharmariese scheitert mit seinem Herzmittel Ziltivekimab in einer zulassungsrelevanten Studie. Es hätte ein milliardenschweres Umsatzpotenzial haben können.

<![CDATA[Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly]]>

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences]]>

<![CDATA[Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons]]>

<![CDATA[Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion]]>

Supernus, Individor merge to beef up brain drug portfolio

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Pa...

Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market

Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a psychedelic mental health sector targeted by companies includi...

<![CDATA[FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease]]>

<![CDATA[Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb]]&...

Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics

The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.

<![CDATA[Eli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs]]>

Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 bil...

Psychedelics developer Definium scores more positive data for LSD pill

Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.